Related Experiment Video
Updated: Aug 18, 2026

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018
Potential involvement of monocyte chemoattractant protein (MCP)-1/CCL2 in IL-4-mediated tumor immunity through
Hui Wang1, Yoko Nemoto-Sasaki, Toshikazu Kondo
1Division of Molecular Bioregulation, Cancer Research Institute, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-0934, Japan.
Abstract:
We previously observed that IL-4 gene transduction into a mouse colon 26 adenocarcinoma cell line abrogated its tumorigenicity due to the generation of anti-tumor CTL. DEC-205- and CD11c-double positive cells were increased in the lymph nodes of mice injected with IL-4-transfected cells between 2 and 3 days after the tumor injection, compared with those injected with parental cells. Most of these double positive cells expressed CD86 antigen. Among the chemokines with chemotactic activities against dendritic cells, monocyte chemoattractant protein (MCP)-1/CCL2, ABCD-1/CCL22, and liver and activation-regulated chemokine (LARC)/CCL20 gene expression was enhanced no later than 3 days after the tumor injection, in the draining lymph nodes of IL-4-transfected cell bearing mice. Moreover, gene expression of the receptor for MCP-1/CCL2, CCR2, was enhanced in the draining lymph nodes of the mice injected with IL-4-transfected cells, and most DEC-205-positive cells in the lymph nodes expressed CCR2. Finally, the administration of anti-MCP-1/CCL2 antibodies retarded the rate of tumor regression in mice injected with IL-4-tranfected cells, concomitantly with a decrease in DEC-205- and CD11c-double positive cell number in the draining lymph nodes. Thus, locally produced MCP-1/CCL2 may be responsible for IL-4-mediated tumor rejection presumably based on the induction of dendritic cell migration into the draining lymph nodes.
Insights
Interleukin-4 (IL-4) gene transfer into colon cancer cells triggers anti-tumor immunity. Monocyte chemoattractant protein-1 (MCP-1) drives dendritic cell migration, crucial for IL-4-mediated tumor rejection.
Area of Science:
- Immunology
- Cancer Biology
- Molecular Biology
Background:
- Interleukin-4 (IL-4) gene transduction into colon 26 adenocarcinoma cells abrogates tumorigenicity.
- This effect is mediated by the generation of anti-tumor cytotoxic T lymphocytes (CTL).
Purpose of the Study:
- To investigate the role of dendritic cell (DC) populations and chemokine expression in IL-4-mediated tumor rejection.
- To elucidate the specific chemokines and receptors involved in DC migration to draining lymph nodes.
Main Methods:
- Analysis of DEC-205 and CD11c double-positive cells in mouse lymph nodes post-tumor cell injection.
- Quantification of chemokine and receptor gene expression (MCP-1/CCL2, CCL22, CCL20, CCR2) in draining lymph nodes.
- Administration of anti-MCP-1/CCL2 antibodies to assess the impact on tumor regression and DC migration.
Main Results:
- IL-4-transfected cells increased DEC-205+/CD11c+ cells expressing CD86 in lymph nodes.
- Enhanced gene expression of MCP-1/CCL2, CCL22, and CCL20 was observed in draining lymph nodes.
- CCR2, the receptor for MCP-1/CCL2, was upregulated in draining lymph nodes, with DEC-205+ cells expressing CCR2.
- Anti-MCP-1/CCL2 antibody administration hindered tumor regression and reduced DC numbers in lymph nodes.
Conclusions:
- Locally produced Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) is critical for IL-4-mediated tumor rejection.
- MCP-1/CCL2 likely induces dendritic cell migration into draining lymph nodes, initiating an anti-tumor immune response.
Related Concept Videos
The Tumor Microenvironment
Differentiation of Common Myeloid Progenitor Cells
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

